Nucleoside-based probes for imaging tumor proliferation using positron emission tomography

Area of Science:

• Nuclear medicine
• Radiochemistry
• Oncology

Background:

• Cancer is a leading cause of death, necessitating early detection for effective therapy.
• Positron emission tomography (PET) offers superior accuracy and sensitivity for cancer detection compared to CT and MRI.
• Fluorodeoxyglucose (FDG) is a common PET probe but suffers from nonspecific accumulation, leading to false positives.

Purpose of the Study:

• To review the radiochemistry and production of radiolabeled thymidine (TdR) and its analogs for PET imaging.
• To explore the potential of TdR analogs as alternative PET probes for cancer detection.
• To address the limitations of in vivo instability associated with radiolabeled TdR.

Main Methods:

• Review of published literature on the radiochemistry and production of (11)C-TdR and (11)C/(18)F-labeled TdR analogs.
• Analysis of the development of TdR analogs for PET imaging of cellular proliferation and DNA synthesis.

Main Results:

• Radiolabeled thymidine (TdR) itself has shown limited success in PET imaging due to in vivo instability.
• Several radiolabeled analogs of TdR have been developed for PET imaging.
• The review presents the radiochemistry and production methods for (11)C-TdR and its (11)C/(18)F-labeled analogs.

Conclusions:

• Radiolabeled thymidine analogs represent a promising area for developing novel PET probes for cancer detection.
• Further research into TdR analogs could overcome the limitations of current PET imaging agents like FDG.
• The presented review provides a comprehensive overview of the current state of radiolabeled TdR analogs in PET imaging.